Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer.

@article{Maluf2006PhaseIS,
  title={Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer.},
  author={Fernando Cotait Maluf and Aliza L Leiser and Carol A. Aghajanian and Paul J Sabbatini and Sandra D Pezzulli and Dennis Chi and Judith K. Wolf and Charles L Levenback and Elwyn Y. Loh and David R. Spriggs},
  journal={International journal of gynecological cancer : official journal of the International Gynecological Cancer Society},
  year={2006},
  volume={16 3},
  pages={1165-71}
}
The aim of this study was to evaluate the activity and toxicity of a tirapazamine (TPZ)/cisplatin drug combination in patients with stage IV or recurrent cervical cancer. The chemotherapy was administered for a maximum of eight cycles every 21 days. TPZ was administered intravenously at 330 mg/m(2) over a 2-h infusion, followed 1 h later by cisplatin intravenously at 75 mg/m(2) over 1 h on day 1. All patients received antiemetics including dexamethasone, ondansetron, and lorazepam. Subsequent… CONTINUE READING